Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
13,876 total articles
ASML sits at the center of the AI infrastructure build-out. Recent results show accelerating revenue and a 2026 guide lift to €43-45B, while management is committing to a 30% capacity increase now (with another potential 30% in 2028). That combination of structural demand and supply-constrained positioning supports a long trade with a 180-trading-d…
Assembly Biosciences (ASMB) offers a way to play a concentrated biotech bet with a strong strategic partner. With positive Phase 1b readouts for two long-acting helicase-primase inhibitors, a Gilead collaboration, and cash into 2028, the stock ($26.81) already discounts some risk but not all of the upside from Phase 2 starts and potential deal flow…
Redwire (RDW) has been punished since its late-May peak as an announced $500M at-the-market offering and sector rotation into SpaceX hammered the stock. At roughly $8.50 and a $2.02B market cap, the company still shows strong top-line momentum and a sizable backlog, while balance-sheet leverage is manageable. This is a tactical long with tight risk…
Amazon’s core secular story hasn’t changed: AWS continues to scale infrastructure revenue and margins while retail and ads provide durable cash flow. At a market cap of roughly $2.66T and a P/E near 29, the stock still prices in execution but not the next leg of AWS margin expansion. This trade idea outlines a practical long with an entry at $246.0…
Zeta Global is one of the few AI-first marketing software companies showing both rapid revenue growth and measurable free cash flow. With a market cap near $5.4B, improving technicals, a strategic Palantir partnership, and FCF of $183.8M, ZETA looks actionable on a breakout with a disciplined stop. This trade idea lays out entry, stop, targets, cat…
<p>Acco Brands (ACCO) trades at bargain multiples, throws off free cash flow of roughly $49M, and yields over 7% — metrics that argue for a constructive long trade on weakness. The company is small-cap, levered, and exposed to cyclical end markets, so position sizing and a clear stop are essential. This idea targets a measured rebound toward prior …
Santos offers asymmetric upside from exposure to LNG and Asian gas markets, advantaged low-cost production in Australia and a string of near-term growth catalysts. We outline a long-term trade with precise entry, stop and target levels, plus the key risks that could derail the thesis.
BJ's Restaurants (BJRI) has ripped to fresh 52-week highs on heavy volume, but the move is backed by solid profitability, healthy free cash flow and a conservative balance sheet. The stock looks actionable on a mid-term (45 trading days) swing with a clear entry, stop and target that balances momentum with valuation discipline.
Erasca has the science, a modality-agnostic RAS/MAPK pipeline and fresh capital. Recent legal and clinical setbacks pushed sentiment into the gutter; that creates a trading opportunity for investors willing to take event risk. This trade targets a mid-term recovery if the company executes on clinical updates and the patent dispute does not derail d…
XPO's operational rebound in North American LTL, durable free cash flow, and visible AI-driven productivity gains make it a constructive long-term trade. Valuation is not cheap, but the combination of improving operating ratios, a $456M free cash flow run-rate and bullish technicals supports a long entry at current levels for a 180-trading-day hori…
Merck (MRK) is a Strong Buy on expectation of a near-term regulatory milestone for its new oncology candidate Lipfendra and continued commercialization of its oncology portfolio. The stock offers a compelling mix of steady cash generation (free cash flow $14.1B), a $315B market cap, and an established commercial engine. We lay out a clear entry, st…
<p>Q2 Holdings' share-price damage feels overstated relative to its fundamentals. The company has moved customers to the cloud, is producing positive free cash flow, and still grows revenue double digits — yet the stock trades nearer its 52-week low than its highs. This trade idea lays out a concrete long entry, stop and target with a clear 180-tra…
Micron’s pullback from its 52-week high has created a defined risk / reward for a mid-term swing. Strong profitability, massive free cash flow, and constrained supply for high-bandwidth memory underpin the bullish case, while sector-level volatility and bearish technicals argue for a disciplined entry, tight stop, and realistic target.
Oracle is navigating near-term margin and license-pressure that keeps the stock under strain. We view the current pullback as a tactical buying opportunity ahead of renewed cloud momentum and AI-driven workloads. Trade plan: enter at $110.00, stop $98.00, target $135.00, horizon 180 trading days.
First Majestic popped after a constructive quarter and two asset sales that de-risk the balance sheet. The company still trades with tight short interest and solid liquidity metrics despite premium valuation metrics. This is a tactical long for a mid-term swing (45 trading days) with defined entry, stop and target.
Micron is the simplest way to play the AI-driven memory cycle without overcomplicating the thesis. The stock has pulled back from its June highs amid sector weakness and macro headlines; fundamentals and cash flow argue for buying this dip with a clearly defined stop and a mid-term target near $1,050.
Adobe is trading at a mid-teens P/E with more than $10 billion in free cash flow, a fortress-like ROE, and visible enterprise demand for content and document AI. Competition is real, but the stock's valuation and strong cash generation make a long trade compelling over the next 180 trading days.
AST SpaceMobile plunged after a $1B convertible-note announcement. I bought a starter position near $60.80 because the selloff appears driven more by dilution fear than changes to the core commercial thesis: direct-to-phone service with carrier partners. With launches in early August and carrier validations in hand, the next 45 trading days offer a…
ImmunityBio (IBRX) is a buy here. The market is discounting ANKTIVA's commercial momentum after an overreaction to promotional conduct headlines earlier this year. With an accepted sBLA, compelling QUILT efficacy numbers, and a PDUFA date of 01/06/2027, the path to re-rating is clear — but not risk-free. Trade plan: enter $7.70, stop $6.50, target …
People Incorporated (PPLI) looks like a classic conglomerate with recognizable consumer-facing assets - digital publishing, home services marketplaces, search and niche staffing platforms. The shares trade at a low price-to-book yet a relatively high price-to-earnings, suggesting the market discounts the asset mix. This trade targets a long-term re…
QuantumScape (QS) just passed a key operational milestone with pilot Eagle Line production and has fresh automaker validation. The stock trades around $5.78 with a market cap of roughly $3.5B and an attractive technical setup for a tactical swing trade. This idea outlines an entry, stop and target for a mid-term trade while laying out the fundament…
Novo Nordisk has moved from broken market leadership to a credible comeback thanks to a successful oral Wegovy pill launch and improving technicals. At a $225.8B market cap and roughly 12x P/E, the stock looks like a recovery trade rather than a growth premium. This idea lays out an actionable long: entry at $50.59, stop at $45.00, target $68.00 ov…
United Community Banks (UCB) has rebuilt core profitability, generates meaningful free cash flow, and is executing accretive M&A and shareholder returns. At roughly $36.60 today, the stock trades at ~13.5x trailing earnings and 1.2x book with a 2.7% yield. We initiate a Buy with a mid-term (45 trading days) price target of $42.00, a tight stop at $…
Encore Capital (ECPG) offers an asymmetric risk-reward for disciplined buyers. The company is executing a sensible refinancing plan, collections and portfolio purchases remain healthy, and shares trade at a single-digit P/E with a 52-week range that still leaves upside. Take a small, defined long position with a clear stop and a multi-month holding…
Moelis & Company (MC) just gave investors a clean entry after a sharp sell-off. The advisory firm still prints high ROE, solid free cash flow and a dividend yield that cushions downside. Technical momentum and falling short interest add to the bull case. Here's a pragmatic trade plan with entry, stop and targets across three horizons.
